Resources
42 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted 11/14/2022 (updated 3/27/2024)
In their new 2022 Clinical Practice Guideline, the Centers for Disease Control and Prevention (CDC) provides updated evidence and research on the risks and benefits of prescription opioids for acute, subacute, and chronic pain. These include dosing strategies, tapering and discontinuation, comparisons with nonopioid pain treatments, and risk mitigation strategies.
Posted 8/10/2022 (updated 3/27/2024)
Researchers looked at what happens in rural and urban emergency departments (EDs) when peer-based services are used for patients arriving with opioid use disorder (OUD). The study aimed to find gaps in knowledge for rural EDs and found five key differences from urban counterparts that presented a challenge. Among these was difficulty identifying community partners.
Posted 8/2/2022 (updated 3/27/2024)
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
Posted 6/8/2022 (updated 3/27/2024)
This “Regional Emergency Disaster Response Preparedness Plan for Substance Use Disorder” workshop was designed to provide attendees with information on the importance of developing a plan to support populations with SUD/OUD during a disaster. Attendees heard how community members in rural and small urban communities are working together to ensure services and supports are available to populations with SUD during a disaster.
Posted 5/25/2022 (updated 3/27/2024)
CDC’s Division of Overdose Prevention has developed an interactive data visualization tool, the DOSE Dashboard, which displays current nonfatal overdose data. The nonfatal drug overdose data on this dashboard are from CDC’s Drug Overdose Surveillance and Epidemiology (DOSE) system, which captures electronic health record information in syndromic surveillance data systems. DOSE data can be used to compare monthly and annual trends in nonfatal drug overdose-related ED visits by drug type (i.e., all drugs, all opioids, heroin, and all stimulants), state, and sex and age group.
Posted 5/3/2022 (updated 3/27/2024)
Buprenorphine utilization is an effective treatment for opioid use disorder (OUD). Given the recent
increase in child maltreatment reports related to parental substance use, research should explore the correlation between buprenorphine treatment and child maltreatment–related outcomes.
Posted 4/26/2022 (updated 3/27/2024)
Background: The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programmes, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).
Posted 3/23/2022 (updated 3/27/2024)
Over the past 20 years, drug overdose deaths have increased dramatically in the United States. Most of these deaths involved opioids, including prescription pain medications, heroin, and synthetic opioids such as fentanyl. These are called opioid-related overdoses and often occur as a result of respiratory depression caused by opioids, even when other medications and drugs are involved.
Posted 3/16/2022 (updated 3/27/2024)
We are pleased to share that the Substance Abuse and Mental Health Services Administration (SAMHSA) has rolled out a new 988 website today – available at samhsa.gov/988. The 988 website is designed to serve as your one-stop-shop for 988 resources from SAMHSA.
Notably, we want to make sure you’re aware that the site contains a 988 partner toolkit. The partner toolkit is intended for SAMHSA’s 988 implementation partners (crisis call centers, state mental health programs, substance use treatment providers, behavioral health systems, and others) to provide key messages, FAQs, and more information about what 988 is and how it will work.